Factor VIII and the risk of arterial thrombosis;Czynnik VIII a ryzyko zakrzepicy tętniczej

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 60, Issue , 2006, Pages 602-608

  Małecki, Rafał ^a   Adamiec, Rajmund ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Arterial thrombosis; Cardiovascular risk factors; Factor VIII

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ATHEROSCLEROSIS; BLOOD CLOTTING; COMORBIDITY; EPIDEMIOLOGY; HEMOPHILIA A; HUMAN; INCIDENCE; METABOLISM; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; THROMBOSIS;

ATHEROSCLEROSIS; BLOOD COAGULATION; CAUSALITY; COMORBIDITY; FACTOR VIII; HEMOPHILIA A; HUMANS; INCIDENCE; RISK FACTORS; THROMBOSIS;

EID: 33847070916     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Ananyeva N.M., Kouiavskaia D.V., Shima M., Saenko E.L.: Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque. Blood, 2002; 99: 4475-4485
2. Bank I., Libourel E.J., Middeldorp S., Hamulyak K., van Pampus E.C., Koopman M.M., Prins M.H., van der Meer J., Buller H.R.: Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J. Thromb. Haemost., 2005; 3: 79-84
3. Begbie M., Notley C., Tinlin S., Sawyer L., Lillicrap D.: The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP. Thromb. Haemost., 2000; 84: 216-222
4. Berliner J.I., Rybicki A.C., Kaplan R.C., Monrad E.S., Freeman R., Billett H.H.: Elevated levels of Factor XI are associated with cardiovascular disease in women. Thromb. Res., 2002; 107: 55-60
5. Bombeli T., Jutzi M., De Conno E., Seifert B., Fehr J.: In patients with deep-vein thrombosis elevated levels of factor VIII correlate only with von Willebrand factor but not other endothelial cell-derived coagulation and fibrinolysis proteins. Blood Coagul. Fibrinolysis, 2002; 13: 577-581
6. Bovenschen N., Mertens K., Hu L., Havekes L.M., van Vlijmen B.J.: LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood, 2005; 106: 906-912
7. Brinkhous K.M., Sandberg H., Garris J.B., Mattsson C., Palm M., Griggs T., Read M.S.: Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc. Natl. Acad. Sci. USA, 1985; 82: 8752-8756
8. Cortellaro M., Boschetti C., Cofrancesco E., Zanussi C., Catalano M., de Gaetano G., Gabrielli L., Lombardi B., Specchia G., Tavazzi L. I wsp.: The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscler. Thromb., 1992; 12: 1063-1070
9. Cunningham N., Laffan M.A., Manning R.A., O'Donnell J.S.: Lowdensity lipoprotein receptor-related protein polymorphisms in patients with elevated factor VIII coagulant activity and venous thrombosis. Blood Coagul. Fibrinolysis, 2005; 16: 465-468
10. Denis C.V., Kwack K., Saffaripour S., Maganti S., Andre P., Schaub R.G., Wagner D.D.: Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. Blood, 2001; 97: 465-472
11. Eaton D., Rodriguez H., Vehar G.A.: Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry, 1986; 25: 505-512
12. Fimognari F.L., De Santis A., Piccheri C., Moscatelli R., Gigliotti F., Vestri A., Attili A., Violi F.: Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis. J. Lab. Clin. Med., 2005; 146: 238-243
13. Folsom A.R., Rosamond W.D., Shahar E., Cooper L.S., Aleksic N., Nieto F.J., Rasmussen M.L., Wu K.K.: Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation, 1999; 100: 736-742
14. Gazzard B.G., Clark R., Flute P.T., Williams R.: Factor VIII levels during the course of acute hepatitis in a haemophiliac. J. Clin. Pathol., 1975; 28: 972-974
15. Geffken D.F., Cushman M., Burke G.L., Polak J.F., Sakkinen P.A., Tracy R.P.: Association between physical activity and markers of inflammation in a healthy elderly population. Am. J. Epidemiol., 2001; 153: 242-250
16. Gitschier J., Wood W.I., Tuddenham E.G., Shuman M.A., Goralka T.M., Chen E.Y., Lawn R.M.: Detection and sequence of mutations in the factor VIII gene of haemophiliacs. Nature, 1985; 315: 427-430
17. Hollestelle M.J., Thinnes T., Crain K., Stiko A., Kruijt J.K., van Berkel T.J., Loskutoff D.J., van Mourik J.A.: Tissue distribution of factor VIII gene expression in vivo-A closer look. Thromb. Haemost., 2001; 86: 855-861
18. Hoppener M.R., Kraaijenhagen R.A., Hutten B.A., Buller H.R., Peters R.J., Levi M.: Beta-receptor blockade decreases elevated plasma levels of factor VIII:C in patients with deep vein thrombosis. J. Thromb. Haemost., 2004; 2: 1316-1320
19. Ingram G.I., Jones R.V.: The rise in clotting factor 8 induced in man by adrenaline: effect of alpha-and beta-blockers. J. Physiol., 1966; 187: 447-454
20. Jeremic M., Weisert O., Gedde-Dahl T.W.: Factor VIII (AHG) levels in 1016 regular blood donors. The effects of age, sex, and ABO blood groups. Scand. J. Clin. Lab. Invest., 1976; 36: 461-466
21. Kahn N.N., Sinha A.K., Spungen A.M., Bauman W.A.: Effects of oxandrolone, an anabolic steroid, on hemostasis. Am. J. Hematol., 2006; 81: 95-100
22. Kamphuisen P.W., Eikenboom J.C., Bertina R.M.: Elevated factor VIII levels and the risk of thrombosis. Arterioscler. Thromb. Vasc. Biol., 2001; 21: 731-738
23. Kamphuisen P.W., Eikenboom J.C., Vos H.L., Pablo R., Sturk A., Bertina R.M., Rosendaal F.R.: Increased levels of factor VIII and fi-brinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb. Haemost., 1999; 81: 680-683
24. Kaufman R.J., Dorner A.J., Fass D.N.: von Willebrand factor elevates plasma factor VIII without induction of factor VIII messenger RNA in the liver. Blood, 1999; 93: 193-197
25. Kerr R.: New insights into haemostasis in liver failure. Blood Coagul. Fibrinolysis, 2003; 14(Suppl.1): S43-S45
26. Kim R.J., Becker R.C.: Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: A meta-analysis of published studies. Am. Heart J., 2003; 146: 948-957
27. Korkmaz C., Ozdogan H., Kasapcopur O., Yazici H.: Acute phase response in familial Mediterranean fever. Ann. Rheum. Dis., 2002; 61: 79-81
28. Koster T., Blann A.D., Briet E., Vandenbroucke J.P., Rosendaal F.R.: Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet, 1995; 345: 152-155
29. Kullo I.J., Gau G.T., Tajik A.J.: Novel risk factors for atherosclerosis. Mayo Clin. Proc., 2000; 75: 369-380
30. Kumagai T., Hoshi Y., Tsutsumi H., Ebina K., Yokota K.: Inhibition of plasma coagulation through interaction between oxidized low-density lipoprotein and blood coagulation factor VIII. Biol. Pharm. Bull., 2005; 28: 952-956
31. Kyrle P.A., Minar E., Hirschl M., Bialonczyk C., Stain M., Schneider B., Weltermann A., Speiser W., Lechner K., Eichinger S.: High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N. Engl. J. Med., 2000; 343: 457-462
32. Lamphear B.J., Fay P.J.: Proteolytic interactions of factor IXa with human factor VIII and factor VIIIa. Blood, 1992; 80: 3120-3126
33. Lenting P.J., Neels J.G., van den Berg B.M., Clijsters P.P., Meijerman D.W., Pannekoek H., van Mourik J.A., Mertens K., van Zonneveld A.J.: The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J. Biol. Chem., 1999; 274: 23734-23739
34. Lollar P., Hill-Eubanks D.C., Parker C.G.: Association of the factor VIII light chain with von Willebrand factor. J. Biol. Chem., 1988; 263: 10451-10455
35. Meade T.W., Cooper J.A., Stirling Y., Howarth D.J., Ruddock V., Miller G.J.: Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br. J. Haematol., 1994; 88: 601-607
36. Meyers K.M., Wardrop K.J., Dodds W.J., Brassard J.: Effect of exercise, DDAVP, and epinephrine on the factor VIII:C/von Willebrand factor complex in normal dogs and von Willebrand factor deficient Doberman pinscher dogs. Thromb. Res., 1990; 57: 97-108
37. Moskau S., Golla A., Grothe C., Boes M., Pohl C., Klockgether T.: Heritability of carotid artery atherosclerotic lesions: an ultrasound study in 154 families. Stroke, 2005; 36: 5-8
38. Mukamal K.J., Cushman M., Mittleman M.A., Tracy R.P., Siscovick D.S.: Alcohol consumption and inflammatory markers in older adults: The Cardiovascular Health Study. Atherosclerosis, 2004; 173: 79-87
39. Noe D.A.: A mathematical model of coagulation factor VIII kinetics. Haemostasis, 1996; 26: 289-303
40. Noe D.A., Murphy P.A., Bell W.R., Siegel J.N.: Acute-phase behavior of factor VIII procoagulant and other acute-phase reactants in rabbits. Am. J. Physiol., 1989; 257: R49-R56
41. O'Donnell J., Mumford A.D., Manning R.A., Laffan M.: Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb. Haemost., 2000; 83: 10-13
42. Orstavik K.H., Magnus P., Reisner H., Berg K., Graham J.B., Nance W.: Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am. J. Hum. Genet., 1985; 37: 89-101
43. Ricci G., Cerneca F., Simeone R., Pozzobon C., Guarnieri S., Sartore A., Pregazzi R., Guaschino S.: Impact of highly purified urinary FSH and recombinant FSH on haemostasis: an open-label, randomized, controlled trial. Hum. Reprod., 2004; 19: 838-848
44. Rick M.E., Esmon N.L., Krizek D.M.: Factor IXa and von Willebrand factor modify the inactivation of factor VIII by activated protein C. J. Lab. Clin. Med., 1990; 115: 415-421
45. Rosendaal F.R., Briet E., Stibbe J., van Herpen G., Leuven J.A., Hofman A., Vandenbroucke J.P.: Haemophilia protects against ischaemic heart disease: A study of risk factors. Br. J. Haematol., 1990; 75: 525-530
46. Rumley A., Lowe G.D., Sweetnam P.M., Yarnell J.W., Ford R.P.: Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br. J. Haematol., 1999; 105: 110-116
47. Smith A., Patterson C., Yarnell J., Rumley A., Ben-Shlomo Y., Lowe G.: Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation, 2005; 112: 3080-3087
48. Souto J.C., Almasy L., Borrell M., Blanco-Vaca F., Mateo J., Soria J.M., Coll I., Felices R., Stone W., Fontcuberta J., Blangero J.: Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am. J. Hum. Genet., 2000; 67: 1452-1459
49. Sramek A., Kriek M., Rosendaal F.R.: Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet, 2003; 362: 351-354
50. Stableforth P., Montgomery D.C., Wilson E., Churchill W.G., Dormandy K.M., Hardisty R.M.: Effect of oral contraceptives on factor VIII clotting activity and factor VIII related antigen in normal women. J. Clin. Pathol., 1975; 28: 498-501
51. Stirling D., Hannant W.A., Ludlam C.A.: Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thromb. Haemost., 1998; 79: 74-78
52. Strickland D.K., Ranganathan S.: Diverse role of LDL receptor-related protein in the clearance of proteases and in signaling. J. Thromb. Haemost., 2003; 1: 1663-1670
53. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., van de Loo J.C.: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N. Engl. J. Med., 1995; 332: 635-641
54. Toschi V., Gallo R., Lettino M., Fallon J.T., Gertz S.D., Fernandez-Ortiz A., Chesebro J.H., Badimon L., Nemerson Y., Fuster V., Badimon J.J.: Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation, 1997; 95: 594-599
55. Tousoulis D., Davies G., Stefanadis C., Toutouzas P., Ambrose J.A.: Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart, 2003; 89: 993-997
56. Tracy R.P., Arnold A.M., Ettinger W., Fried L., Meilahn E., Savage P.: The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler. Thromb. Vasc. Biol., 1999; 19: 1776-1783
57. Ural A.U., Yilmaz M.I., Avcu F., Yalcin A.: Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components. Int. J. Hematol., 2002; 76: 279-283
58. Varfaj F., Neuberg J., Jenkins P.V., Wakabayashi H., Fay P.J.: Role of P1 residues Arg336 and Arg562 in the activated-Protein-C-catalysed inactivation of Factor VIIIa. Biochem. J., 2006; 396: 355-362
59. Voetsch B., Loscalzo J.: Genetic determinants of arterial thrombosis. Arterioscler. Thromb. Vasc. Biol., 2004; 24: 216-229
60. Wattanakit K., Folsom A.R., Chambless L.E., Nieto F.J.: Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am. Heart. J., 2005; 149: 606-612